Comparison of the Effects of Govarcin Herbal Capsule and Metoclopramide for Alleviating Gastrointestinal Symptoms in Patients with Functional Dyspepsia : A Randomized Double-blind Clinical Trial
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Functional dyspepsia (FD) is felt as a discomfort or pain on the center line or upper abdomen. In this study, we investigated the effect of Govarcin herbal capsule on FD so that if it is effective, it can be used in the treatment of patients with this disease.
METHODS: Totally, 106 patients enrolled in a double-blind, clinical trial study. The participants had FD and were divided into two groups receiving Govarcin and Metoclopramide by block randomization. The patients were treated for four weeks, taking one Govarcin capsule or Metoclopramide tablet after each meal. The rate of improvement in patients was assessed by mitigation of clinical symptoms, including epigastric pain, fullness, discomfort, nausea, vomiting and heartburn. Also, before and after intervention, we used Nepin questionnaire and ROME III. SPSS statistics 25 software was used for data analyzing.
RESULTS: Clinical symptom score changes between Govarcin and Metoclopramide patients' groups showed that there was no significant difference in any of the clinical symptom scores (except for heartburn, p-vale=0.012) between the study groups. Nepean score in Govarcin group before and after treatment was 19.3±4.8 and 8.9±2.8, respectively (p-value<0.001). For Metoclopramide group, these values were 19.8±3.5 and 9.4±2.1 respectively (p-value<0.001). No significant difference was found in terms of Nepean score between the Govarcin and Metoclopramide groups (p-value=0.995).
CONCLUSION: Govarcin herbal capsule can be used to remedy symptoms in patients with FD. It seems that Guarcin is as effective as metoclopramide in fighting symptoms of FD as no significant difference in efficacy has been demonstrated between them.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Reviews on recent clinical trials - (2023) vom: 01. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Asghari, Majid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial |
|---|
| Anmerkungen: |
Date Revised 15.12.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0115748871266848231120112355 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365902314 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365902314 | ||
| 003 | DE-627 | ||
| 005 | 20231227132533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0115748871266848231120112355 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1228.xml |
| 035 | |a (DE-627)NLM365902314 | ||
| 035 | |a (NLM)38099534 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Asghari, Majid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of the Effects of Govarcin Herbal Capsule and Metoclopramide for Alleviating Gastrointestinal Symptoms in Patients with Functional Dyspepsia |b A Randomized Double-blind Clinical Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Functional dyspepsia (FD) is felt as a discomfort or pain on the center line or upper abdomen. In this study, we investigated the effect of Govarcin herbal capsule on FD so that if it is effective, it can be used in the treatment of patients with this disease | ||
| 520 | |a METHODS: Totally, 106 patients enrolled in a double-blind, clinical trial study. The participants had FD and were divided into two groups receiving Govarcin and Metoclopramide by block randomization. The patients were treated for four weeks, taking one Govarcin capsule or Metoclopramide tablet after each meal. The rate of improvement in patients was assessed by mitigation of clinical symptoms, including epigastric pain, fullness, discomfort, nausea, vomiting and heartburn. Also, before and after intervention, we used Nepin questionnaire and ROME III. SPSS statistics 25 software was used for data analyzing | ||
| 520 | |a RESULTS: Clinical symptom score changes between Govarcin and Metoclopramide patients' groups showed that there was no significant difference in any of the clinical symptom scores (except for heartburn, p-vale=0.012) between the study groups. Nepean score in Govarcin group before and after treatment was 19.3±4.8 and 8.9±2.8, respectively (p-value<0.001). For Metoclopramide group, these values were 19.8±3.5 and 9.4±2.1 respectively (p-value<0.001). No significant difference was found in terms of Nepean score between the Govarcin and Metoclopramide groups (p-value=0.995) | ||
| 520 | |a CONCLUSION: Govarcin herbal capsule can be used to remedy symptoms in patients with FD. It seems that Guarcin is as effective as metoclopramide in fighting symptoms of FD as no significant difference in efficacy has been demonstrated between them | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Govarcin | |
| 650 | 4 | |a Nepean score | |
| 650 | 4 | |a functional dyspepsia | |
| 650 | 4 | |a heartburn. | |
| 650 | 4 | |a metoclopramide | |
| 650 | 4 | |a vomiting | |
| 700 | 1 | |a Ahmadpour, Sajjad |e verfasserin |4 aut | |
| 700 | 1 | |a Molazadeh, Mikaeil |e verfasserin |4 aut | |
| 700 | 1 | |a Jafari, Mohammad Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Hormati, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Pashaei, Mohammad Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadpour, Yousef |e verfasserin |4 aut | |
| 700 | 1 | |a Habibi, Mohamad Amin |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadbeigi, Abolfazl |e verfasserin |4 aut | |
| 700 | 1 | |a Hoseini, Seyed Mahmoud Eshagh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews on recent clinical trials |d 2006 |g (2023) vom: 01. Dez. |w (DE-627)NLM178749699 |x 1876-1038 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:01 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0115748871266848231120112355 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 01 |c 12 | ||